Abstract 867P
Background
Oropharyngeal squamous cell cancer (OPSCC) related to Human Papilloma Virus (HPV) is a subgroup of head and neck cancer that can be identified by p16 immunohistology and HPV-DNA testing. Although the prognosis is generally favorable, there has been a lack of success in implementing therapy de-escalation, owing to the heterogeneity of the disease. This underscores the need for precise biomarkers to facilitate patient stratification.
Methods
Our retrospective, multi-institutional study enrolled 906 patients and utilized deep learning to develop an algorithm that accurately predict HPV-association and strongly correlates with prognosis, based on regular H&E slides.
Results
When comparing our algorithm with HPV status, it showed good overall performance (AUROC = 0.83; 95% CI=0.77-0.9). In a subset of the validation cohort (n=639) the implementation of a fixed threshold for filtering resulted in increased AUROC to 0.88, with n=258 cases meeting threshold criteria. The algorithm was compared to the gold standard of HPV-testing in terms of its prognostic relevance and produced better results than the HPV test, indicated by its higher likelihood-ratio test value (LR, 49.23, p<0.001), higher concordance index (0.71), and higher 5-year overall survival rate (OS, 96%, 95% CI=90-100%). In contrast, the HPV test had lower LR (39.72, p<0.001), lower concordance index (0.65), and lower OS (80%, 95% CI=71-90%). The multivariate analysis using three prognostic groups demonstrated good discrimination. The algorithm had a high hazard ratio (HR) of 0.15 (95% CI=0.05-0.44) for the high-risk group, a medium HR of 0.58 (95% CI=0.34-0.98) for the intermediate-risk group, and a significant p-value of 0.043 for the entire group of 211 patients. In comparison, HPV testing had an HR of 0.29 (95% CI=0.15-0.54) and a highly significant p-value of <0.001 for the same group of 211 patients.
Conclusions
Our algorithm can identify patients with OPSCC who have a favorable prognosis using standard hematoxylin and eosin (H&E) histologic slides. In multiple scenarios, our stratification method performs better than the gold standard (p16/HPV-DNA) and could potentially be used to select patients for therapy de-escalation strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
890P - Real-world survival outcomes and survival risk factors in elderly patients with locally advanced squamous cell carcinoma of the head and neck
Presenter: Nabil Saba
Session: Poster session 12
891P - Changing landscape of head and neck squamous cell carcinoma (HNSCC) treatment and survival in Thailand: A 13-year multicenter retrospective study of 6,319 patients
Presenter: Nuttapong Ngamphaiboon
Session: Poster session 12
892P - Real-world data validation of university of San Diego nomogram for the prediction of benefit of intensive treatment for locoregionally advanced head and neck cancer
Presenter: Javier Caballero Daroqui
Session: Poster session 12
893P - Tumor node stage shift following leukocyte interleukin injection neoadjuvant extends overall survival in treatment-naïve locally advanced oral cavity/soft palate squamous cell carcinoma
Presenter: Jozsef Timar
Session: Poster session 12
894P - Is pathological complete response (PCR) a surrogate endpoint of overall survival in patients with technically unresectable oral cavity cancers? A real-world data study of 900 plus patients
Presenter: Shatabdi Chakraborty
Session: Poster session 12
896P - Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
Presenter: Kai Wang
Session: Poster session 12
897P - Nanosomal docetaxel lipid suspension (NDLS) or docetaxel based neoadjuvant therapy in Head and neck squamous cell carcinoma: Post hoc analysis of a prospective, randomized study
Presenter: Darshit Shah
Session: Poster session 12
898P - Meta-analysis of two placebo-controlled trials of avasopasem manganese (AVA) in patients with locally advanced, head & neck cancer (LAHNC)
Presenter: Neal Dunlap
Session: Poster session 12
899P - Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Presenter: Berta Vilar Anglada
Session: Poster session 12